Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy

Pulmonary Embolism Clinical Trial

— Pot-Kast  

Official title:

Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01542723
• Other study ID #: NL35774.058.11(2)
• Status: Completed
• Phase: N/A
• First received: February 27, 2012
• Last updated: October 10, 2016
• Start date: May 2012
• Est. completion date: September 2016

Study information

• Verified date: October 2016
• Source: Leiden University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.

Description:

Background:

Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy exists. In the proposed study we will use relevant symptomatic endpoints in a large cohort of patients. Furthermore we will follow subjects with an adverse event for a longer period, during which we will assess the long term sequelae of these events. Lastly, we will determine high risk groups that will benefit most from anticoagulant treatment.

Objective:

Comparative effectiveness research to determine cost-effectiveness of an existing healthcare policy, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition we will investigate personalized prophylaxis based on genetic and acquired risk factors.

Study Design:

A randomized controlled trial comparing a policy with the anticoagulant LMWH to a policy with no anticoagulant in patients who underwent knee arthroscopy.

Determination of genetic and acquired risk factors will be performed at the start of the study. Based on the presence or absence of these factors we will assign a risk profile to each patient

Study Population:

The study population will consist of 1500 patients undergoing knee arthroscopy. These patients will be recruited from 6 hospitals in the Leiden/Den Haag region over a two-year inclusion period. All patients over 18 years will be eligible, except patients with a contra-indication or an absolute indication for LMWH use

Intervention:

LMWH (for example nadroparin 2850 IE s.c. once daily, > 100kg 5700IE sc) for 8 days vs no treatment.

Each hospital will use a LMWH according to their own preference.

Blood taken pre- and post-operatively will be analyzed on common single nucleotide polymorphisms (SNPs) known to strongly affect thrombotic risk; on levels of coagulation factors in plasma (of which high or low levels are known to increase the risk). Patients will also be screened on acquired risk factors for thrombosis through a questionnaire.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

We will compare two standard treatment modes that are currently both used depending on the physician's or hospital's preference. The patients in our trial will be subjected to one of these standard treatments. It is therefore not expected that participation will lead to an increased health risk. LMWHs like Nadroparin and Dalteparin are no experimental pharmaceuticals; both have been registered in the Netherlands for these indications since 1989.

Not participating in the trial may, depending on the physician, still lead to treatment with an LMWH.

All patients will need to undergo two venepunctures for blood sampling for the study. These blood samples will be taken pre-operatively and post-operatively. No extra hospital visits are required. Patients will be contacted by an electronic questionnaire 2 weeks and 6 weeks after the arthroscopy of the knee and by telephone after three months.

One questionnaire concerning risk factors for thrombosis, bleeding and patients demographics will be filled in before arthroscopy of the knee.

Only subjects with clinically relevant adverse events (and a similar random sample of subjects without a clinically relevant adverse event) will be monitored for a two year period after the event (in total expected to be about 30 subjects). After six months, one year and two years after the event, patients will be seen for clinical examination and quality of life assessment by means of a questionnaire.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: September 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meniscectomy

• Diagnostic Arthroscopy

• Removal of corpora libera

Exclusion Criteria:

• Contra-indications for LMWH use (recent major bleeding, bleeding disorder, allergy)

• Pregnancy

• Pre-existent indication for anticoagulation therapy, either LMWH or vitamin K antagonists.

• History of venous thromboembolism (indication for anticoagulation therapy for prophylaxis of recurrence)

• Mental of physical disability to fulfill study requirements

• Insufficient knowledge of the Dutch language

• Previous participation in the Pot-(K)Cast study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Deep Venous Thrombosis
• Embolism
• Pulmonary Embolism
• Thrombosis
• Venous Thrombosis

Intervention

Drug:
• LMWH
Each hospital will use a LMWH according to their own preferences. Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).

Locations

Country	Name	City	State
Netherlands	Orthopedium	Delft	Zuid-Holland
Netherlands	Reinier de Graaf Groep	Delft	Zuid-Holland
Netherlands	HagaZiekenhuis	Den Haag	Zuid-Holland
Netherlands	Medisch Centrum Haaglanden	Den Haag	Zuid-Holland
Netherlands	Groene Hart Ziekenhuis	Gouda	Zuid-Holland
Netherlands	Leiden University Medical Center	Leiden	Zuid-Holland
Netherlands	Alrijne Ziekenhuis	Leiderdorp	Zuid Holland
Netherlands	PARK MC	Rotterdam	Zuid-Holland
Netherlands	Isala Klinieken	Zwolle	Overijsel

Sponsors (2)

Lead Sponsor	Collaborator
Suzanne C. Cannegieter, MD PhD	ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptomatic deep venous thrombosis (DVT)	Symptomatic deep venous thrombosis confirmed with compression ultrasonography	3 Months	No
Primary	Pulmonary Embolism (PE)	Fatal or non-fatal pulmonary embolism confirmed with: an intraluminal filling defect in segmental or more proximal branches on spiral CT scan, or; a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan, or; detected at autopsy	3 months	No
Primary	Major Bleeding	Major bleeding, defined as: a fatal bleeding, or; symptomatic bleeding in a critical area or organ, or; extrasurgical site bleeding causing a fall in hemoglobin level of 1.24mmol/L (2.0g/dL) or more, leading to transfusion of one or more units of whole blood or red cells, or; surgical site bleeding that requires a second intervention or a hemarthrosis interfering with rehabilitation, or surgical site bleeding that needs blood suppletion.	3 months	Yes
Secondary	Other clinically relevant bleeding	Other clinically relevant bleeding, defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.	3 months	Yes
Secondary	Surgical site infection	Superficial incisional surgical site infection, deep incisional surgical site infection of organ/space surgical site infection according to the definitions of the CDC.	3 months	Yes